MK 7622

Drug Profile

MK 7622

Alternative Names: MK-7622

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Class 3-ring heterocyclic compounds; Antidementias; Pyridines; Quinazolinones; Small molecules
  • Mechanism of Action Muscarinic M1 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 18 Apr 2016 Merck terminates a phase IIa/IIb trial for Alzheimer's disease (Adjunctive treatment) in USA and Canada (NCT01852110)
  • 24 Dec 2015 MK 7622 is still in phase II trials for Alzheimer's disease (Adjunctive treatment) in USA
  • 24 Dec 2015 Phase-II clinical trials in Alzheimer's disease (Adjunctive treatment) in Canada (PO) (NCT01852110)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top